<DOC>
	<DOCNO>NCT02415985</DOCNO>
	<brief_summary>To describe pharmacokinetics rifabutin 150 mg daily versus rifabutin 300 mg thrice weekly combination LPV/r 400/100mg base HAART HIV/TB infect patient</brief_summary>
	<brief_title>Pharmacokinetics Safety Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly</brief_title>
	<detailed_description>The overall aim project evaluate rifabutin replacement rifampicin , combine treatment tuberculosis HIV infection . Rifabutin represent alternative rifampicin HIV infect patient half-life longer enzymatic induction effect appear less important associate ART drug . This phase II trial determine precisely pharmacokinetics parameter rifabutin combination LPV/r regimens Thai HIV/TB infect patient , order define optimal dos test large phase III trial compare safety , tolerability efficacy rifabutin rifampicin regimen .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>1 . Confirmed HIV positive voluntary counseling test 2 . Aged &gt; 1860years age 3 . PInaïve ( NNRTI intolerance/failure ) PI experience ( TB develop salvage regimen ) without prior PI mutation 4 . Any CD4 cell count 5 . ALT &lt; 5 time ULN 6 . Serum creatinine &lt; 1.4 mg/dl 7 . Hemaglobin &gt; 7 mg/L 8 . TB diagnose plan receive stable dos rifabutin contain antiTB therapy least another 4 week period initiation ART 9 . No active OI ( CDC class C event ) , except oral candidiasis disseminate MAC 10 . Body weight &gt; 40kg 11 . Able provide write informed consent 1 . Current use steroid ( except short course steroid IRIS ) immunosuppressive agent . 2 . Current use prohibit medication related drug pharmacokinetics . 3 . Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct trial . 4 . Unlikely able remain followup protocol define period . 5 . Patients proven suspect acute hepatitis . Patients chronic viral hepatitis eligible provide ALT , AST &lt; 5 x ULN . 6 . Karnofsky performance score &lt; 30 % 7 . TB meningitis bone/joints ( due long period anti TB drug ) 8 . Pregnancy 9 . Patient choose use efavirenz , LPV/r . However , ART naïve , EFV allow intensive PK LPV/r rifabutin week 24 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pharmacokinetics rifabutin</keyword>
	<keyword>HIV/TB co-infection</keyword>
	<keyword>resource limit set</keyword>
	<keyword>AUC</keyword>
	<keyword>Cmax</keyword>
	<keyword>Cmin</keyword>
	<keyword>Ctrough</keyword>
</DOC>